PPBT Kitov Pharma: ערך חשבונאי למניה

The investment potential of Purple Biotech is based on management's drive to commercialize methods for combating tumor resistance. The book value per common share illustrates capital dynamics, where the current value stands at 7.52. The foundation for success is built upon targeted developments recognized within the oncology community and strategic ownership of all patents, combined with the effective delegation of clinical trials to external partners.

Purple Biotech (PPBT) possesses significant pricing power in oncology due to the uniqueness of the CM24 antibody, creating substantial potential for the capitalization of intellectual assets. By analyzing the historical book value chart, an investor assesses the residual equity per share after all liabilities are settled, which allows for the determination of the business's intrinsic value and the mitigation of stagnation risks during periods of market consolidation.